Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma
- First Posted Date
- 2010-05-14
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 18
- Registration Number
- NCT01123304
- Locations
- ๐บ๐ธ
John Wayne Cancer Institute, Santa Monica, California, United States
An Open Label Extension Study of the Efficacy of MORAb-003
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 3
- Registration Number
- NCT01018563
- Locations
- ๐บ๐ธ
Sharp Memorial Hospital, Chula Vista, California, United States
๐ฉ๐ชNationales Centrum fur Tumorerkrandungen, Heidelberg, Germany
๐บ๐ธSouth Texas Oncology & Hematology, San Antonio, Texas, United States
Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-10-29
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 15
- Registration Number
- NCT01004380
- Locations
- ๐บ๐ธ
Schwartz Gynecologic Oncology, Brightwaters, New York, United States
๐บ๐ธInternational Beneficence Clinical Research, LLC, Harlingen, Texas, United States
๐บ๐ธJohns Hopkins University, Baltimore, Maryland, United States
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
- Conditions
- Interventions
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 1100
- Registration Number
- NCT00849667
- Locations
- ๐บ๐ธ
Hematology Oncology P.C., Stamford, Connecticut, United States
๐บ๐ธLoyola University Chicago, Maywood, Illinois, United States
๐บ๐ธMercy Medical Center, Baltimore, Maryland, United States
A Study of of MORAb-004 in Subjects With Solid Tumors
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 80
- Registration Number
- NCT00847054
- Locations
- ๐บ๐ธ
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 89
- Registration Number
- NCT00738582
- Locations
- ๐บ๐ธ
Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
๐บ๐ธUniversity of California, San Francisco, San Francisco, California, United States
๐ฉ๐ชAsklepios Fachkliniken Mรผchen-Gauting, Gauting, Germany
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 415
- Registration Number
- NCT00738699
- Locations
- ๐บ๐ธ
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธInnovative Medical Research of South Florida, Inc., Miami, Florida, United States
๐บ๐ธWeinberg Cancer Institute at Franklin Square, Baltimore, Maryland, United States
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 155
- Registration Number
- NCT00570713
- Locations
- ๐บ๐ธ
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
๐บ๐ธSouth Carolina Oncology Associates, PA, Columbia, South Carolina, United States
๐บ๐ธUniversity of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer
- Conditions
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 24
- Registration Number
- NCT00428766
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 24
- Registration Number
- NCT00325494
- Locations
- ๐บ๐ธ
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
๐บ๐ธNational Cancer Institute, Bethesda, Maryland, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States